Alnylam Pharmaceuticals Trading Volume Surges to $342 Million Ranking 272nd in Daily Volume Despite 2.39% Stock Price Decline

On July 11, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant surge in trading volume, reaching $342 million, marking an 116.43% increase from the previous day. This placed Alnylam among the top 272 stocks by trading volume for the day. However, the stock price closed down 2.39%.

Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNA interference (RNAi) therapeutics, has been in the spotlight recently due to several key developments. The company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its new drug, Onpattro, which is designed to treat hereditary transthyretin amyloidosis (hATTR). This approval is a significant milestone for Alnylam, as it marks the first RNAi therapeutic to receive FDA approval.

In addition to the FDA approval, Alnylam has also been making strides in its clinical pipeline. The company reported positive interim results from a Phase 3 clinical trial for its investigational drug, patisiran, which is being developed to treat hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). The results showed that patisiran significantly reduced the progression of neuropathy in patients compared to a placebo.

Furthermore, Alnylam has been expanding its partnerships and collaborations to advance its RNAi therapeutics. The company recently announced a strategic collaboration with Sanofi, a global pharmaceutical company, to develop and commercialize RNAi therapeutics for cardiovascular diseases. This collaboration is expected to accelerate the development of new treatments for patients suffering from these diseases.

Despite these positive developments, Alnylam's stock price has been volatile in recent months. Investors have been closely monitoring the company's progress in its clinical trials and regulatory approvals, as well as its partnerships and collaborations. The recent FDA approval and positive clinical trial results have provided a boost to investor confidence, but the stock price remains sensitive to any new developments or setbacks in the company's pipeline.